McGann PT, Williams TN, Olupot-Olupot P, Tomlinson GA, Lane A, Luís Reis da Fonseca J, Kitenge R, Mochamah G, Wabwire H, Stuber S, Howard TA, McElhinney K, Aygun B, Latham T, Santos B, Tshilolo L, Ware RE
(American Journal of Hematology, 2018-08)
Despite its well-described safety and efficacy in the treatment of sickle cell anemia
(SCA) in high-income settings, hydroxyurea remains largely unavailable in sub-Saharan
Africa, where more than 75% of annual SCA births ...